TY - JOUR
T1 - Use of pristinamycin for Macrolide-Resistant mycoplasma genitalium infection
AU - Read, Tim R.H.
AU - Jensen, Jørgen S.
AU - Fairley, Christopher K.
AU - Grant, Mieken
AU - Danielewski, Jennifer A.
AU - Su, Jenny
AU - Murray, Gerald L.
AU - Chow, Eric P.F.
AU - Worthington, Karen
AU - Garland, Suzanne M.
AU - Tabrizi, Sepehr N.
AU - Bradshaw, Catriona S.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated pristinamycin for macrolide-resistant M. genitalium in a sexual health center in Australia. Microbiologic cure was determined by M. genitalium-specific 16S PCR 14-90 days after treatment began. Of 114 persons treated with pristinamycin, infection was cured in 85 (75%). This percentage did not change when pristinamycin was given at daily doses of 2 g or 4 g or at 3 g combined with 200 mg doxycycline. In infections with higher pretreatment bacterial load, treatment was twice as likely to fail for each 1 log10 increase in bacterial load. Gastrointestinal side effects occurred in 7% of patients. Pristinamycin at maximum oral dose, or combined with doxycycline, cured 75% of macrolide-resistant M. genitalium infections. Pristinamycin is well-tolerated and remains an option where fluoroquinolones have failed or cannot be used.
AB - High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated pristinamycin for macrolide-resistant M. genitalium in a sexual health center in Australia. Microbiologic cure was determined by M. genitalium-specific 16S PCR 14-90 days after treatment began. Of 114 persons treated with pristinamycin, infection was cured in 85 (75%). This percentage did not change when pristinamycin was given at daily doses of 2 g or 4 g or at 3 g combined with 200 mg doxycycline. In infections with higher pretreatment bacterial load, treatment was twice as likely to fail for each 1 log10 increase in bacterial load. Gastrointestinal side effects occurred in 7% of patients. Pristinamycin at maximum oral dose, or combined with doxycycline, cured 75% of macrolide-resistant M. genitalium infections. Pristinamycin is well-tolerated and remains an option where fluoroquinolones have failed or cannot be used.
UR - http://www.scopus.com/inward/record.url?scp=85040922783&partnerID=8YFLogxK
U2 - 10.3201/eid2402.170902
DO - 10.3201/eid2402.170902
M3 - Article
AN - SCOPUS:85040922783
VL - 24
SP - 328
EP - 335
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
SN - 1080-6040
IS - 2
ER -
